Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Clinical trial NCT04208178 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04208178
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-16
- Primary completion
- 2027-02-26
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.